Richard Schatz, M.D., (center) is research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program. #SCAI, #SCAI2018

Here is an aggregation of all the news and late-breaking studies presented at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. 

 

Late-breaking Studies:

May 14, 2018 — Diagnostic and Interventional Cardiology (DAIC) magazine was honored with a Silver national Azbee Award for editorial excellence at the 2018 National American Society of Business Publication Editors (ASBPE)  Azbee Awards of Excellence banquet in May in Washington, D.C.  DAIC and Editor Dave Fornell were recognized in the Online Blog Analysis/Commentary category for Fornell’s blog series “Insights Into Cardiovascular Technology Advances.”

Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from the U.S. Food and Drug Administration (FDA) to enroll a second group of subjects and expand to 15 heart centers across the United States.

TREAT Symposium (TransRadial Endovascular Advanced Therapies)

A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR). This first-ever tool calculates a score to help clinicians and medical professionals predict risk of 30-day readmission for TAVR patients and can be easily incorporated in patient electronic medical records (EMR). The study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego.

Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego. The FLARE study is a prospective, single-arm multicenter trial designed to evaluate the safety and efficacy of the Flowtriever system (Inari Medical, Irvine, Calif.) in patients with acute pulmonary embolism (PE). It is the first trial to treat pulmonary embolism without using thrombolytics, the use of drugs to break up or dissolve blood clots that can lead to bleeding complications.

 

May 11, 2018 — Two studies examining seasonal variations in cardiac-related hospitalizations, specifically for aortic dissection and ST-Elevation Myocardial Infarctions (STEMI), revealed winter as the most common time for hospital admissions. This was according to a study of the Nationwide Inpatient Sample database (NIS) used for the analysis. Results were presented recently at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions.

Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early feasibility study at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, April 25-28 in San Diego. Data from 18 patients followed out to two years revealed the Harmony TPV showed solid valve function and no paravalvular leak (PVL).

EnvoyAI announced a new integration with Insignia Medical Systems’ InSight PACS (picture archiving and communication system) to provide artificial intelligence (AI)-enhanced imaging workflows to customers. For initial launch in the U.K., this integration provides curated AI content available on the EnvoyAI platform within the PACS environment at multiple integration points.  These include AI results viewing directly within the PACS viewer, as well as within the already established Insignia integration with TeraRecon.

May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial setting was presented as late-breaking clinical science at the recent 2018 Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions. The prospective, single-arm, multi-center, observational study entitled, "The Abbott Post-Approval Study 1 MitraClip Registry: 1-year Results of the First 2,000 Patients in the Transcatheter Valve Therapy Registry," is the first to include echocardiographic, functional and quality of life outcomes.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now